ATAI Life Sciences NV
9VC
Company Profile
Business description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Contact
Wallstrasse 16
BerlinBB10179
DEUT: +49 8921539035
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
54
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,580.00 | 6.70 | -0.08% |
| CAC 40 | 7,734.40 | 130.04 | -1.65% |
| DAX 40 | 23,629.58 | 369.59 | -1.54% |
| Dow JONES (US) | 41,603.07 | 256.02 | -0.61% |
| FTSE 100 | 8,717.97 | 21.29 | -0.24% |
| HKSE | 23,530.36 | 70.90 | -0.30% |
| NASDAQ | 18,737.21 | 188.53 | -1.00% |
| Nikkei 225 | 37,329.22 | 168.75 | 0.45% |
| NZX 50 Index | 12,547.69 | 48.81 | -0.39% |
| S&P 500 | 5,802.82 | 39.19 | -0.67% |
| S&P/ASX 200 | 8,351.40 | 9.50 | -0.11% |
| SSE Composite Index | 3,360.93 | 12.56 | 0.38% |